X. Buthaud

Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.

F. Goldwasser, J. Misset, C. Jasmin, 1999, Anti-cancer drugs.

Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).

F. Denis, D. Pasquier, V. Beckendorf, 2019, International journal of radiation oncology, biology, physics.

Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?

N. Magné, E. Deniaud-Alexandre, Y. Belkacemi, 2020, Cancers.

[State of the art and advances in radiotherapy for bladder cancer].

P. Bondiau, M. Housset, J. Thariat, 2009, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.

N. Magné, D. Peiffert, F. Denis, 2021, European urology.

Oligopelvis-GETUG P07: A multicenter phase II trial of combined salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses of prostate cancer.

N. Magné, F. Denis, D. Pasquier, 2020 .

Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients

N. Magné, E. Deniaud-Alexandre, Y. Belkacemi, 2018, PloS one.

Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy

J. Pierga, L. Chauveinc, V. Mosseri, 2003, British Journal of Cancer.